Diabetic macular edema, which is a manifestation of diabetic retinopathy, affects approximately 750,000 people in the United States and is a leading cause of vision loss. In recent years, there has been a revolutionary paradigm shift in the treatment of diabetic retinopathy. Intravitreal therapy has rapidly supplanted focal/grid laser as the standard of care, and the role of angiogenesis and inflammation in the pathogenesis of diabetic retinopathy has been elucidated. In addition, the development of new delivery systems for anti-VEGF therapy and steroids offers improved characteristics that make them valuable additions to the armamentarium.
This program will review the role of angiogenesis and inflammation in the pathogenesis of diabetic retinopathy, explore the diagnostic evaluation of the diabetic retina, and review current and emerging therapies in order to improve the standard of care for this sight-threatening disease.